HERCULES, CA -- (Marketwire) -- 01/06/10 --
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced today that it has completed the purchase of certain diagnostics businesses of Biotest AG, including its diagnostics products in the areas of blood transfusion testing, transplantation, and infectious diseases for 45 million euros
Bio-Rad signed a definitive agreement to acquire these diagnostics businesses of Biotest on October 23, 2009
"We are pleased with the opportunity to expand our product offering in the area of immunohematology," said Norman Schwartz, Bio-Rad President and CEO
"Integrating Biotest diagnostics products into our current offering will further strengthen Bio-Rad's position in this area and enable us to provide our customers, including those in the U.S., with a broader range of products and services."
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,500 people globally and had revenues exceeding $1.7 billion in 2008. For more information, visit www.bio-rad.com
About Biotest
Biotest is a provider of pharmaceutical and biotherapeutic drugs as well as reagents and systems for microbiology. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of application of immunology and haematology. In its Plasma Protein segment, Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In the Biotherapeutic segment, Biotest researches into the clinical development of monoclonal antibodies, including in the indications of rheumatoid arthritis and cancer of plasma cells. The products of the Microbiological Monitoring segment are primarily used in hygiene monitoring. Biotest has more than 1,900 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities
and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements
For more information contact: Bio-Rad Laboratories, Inc
Tina Cuccia Corporate Communications 510-724-7000 Email Contact
Biotest AG Dr. Monika Buttkereit +49 (0) 6103 801-4406 Email Contact
http://ih.advfn.com/p.php?pid=nmona&cb=1262895164&article=40983335&symbol=NY%5EBIO
Recent BIO News
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/09/2024 08:30:20 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/08/2024 08:38:02 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:31:24 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2024 06:25:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:18:26 PM
- Bio-Rad Reports First-Quarter 2024 Financial Results • Business Wire • 05/07/2024 08:15:00 PM
- Bio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference • Business Wire • 05/01/2024 01:00:00 PM
- Bio-Rad Announces Life Science Group Management Changes • Business Wire • 04/26/2024 12:30:00 PM
- Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 • Business Wire • 04/18/2024 01:00:00 PM
- Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay • GlobeNewswire Inc. • 04/11/2024 09:30:00 PM
- Bio-Rad’s Chief Operating Officer Andrew Last to Retire • Business Wire • 04/10/2024 08:15:00 PM
- Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer • Business Wire • 03/20/2024 12:30:00 PM
- Bio-Rad to Participate in Fireside Chat During Citi's 2024 Unplugged Medtech and Life Sciences Access Day • Business Wire • 02/22/2024 09:30:00 PM
- Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results • Business Wire • 02/15/2024 09:15:00 PM
- Bio-Rad to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024 • Business Wire • 01/24/2024 10:00:00 PM
- Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan’s 42nd Annual Healthcare Conference • Business Wire • 01/02/2024 09:15:00 PM
- Bio-Rad Reports Third-Quarter 2023 Financial Results • Business Wire • 10/26/2023 08:15:00 PM
- Bio-Rad to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023 • Business Wire • 10/05/2023 12:30:00 PM
- Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 2023 Healthcare Conference • Business Wire • 08/28/2023 08:15:00 PM
- Bio-Rad Reports Second-Quarter 2023 Financial Results • Business Wire • 08/03/2023 08:15:00 PM
- Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement • Business Wire • 07/26/2023 08:15:00 PM
- Bio-Rad Announces New Share Repurchase Program • Business Wire • 07/20/2023 08:30:00 PM
- Bio-Rad to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023 • Business Wire • 07/10/2023 08:30:00 PM
- Bio-Rad Publishes Corporate Sustainability Report for 2022 • Business Wire • 07/10/2023 01:00:00 PM
- Bio-Rad to Present Company Overview at Jefferies Healthcare Conference • Business Wire • 06/01/2023 12:00:00 PM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM